Earnings call transcript: Zynex Inc Q2 2025 reveals unexpected loss, stock plunges

Zynex Inc (ZYXI) reported a significant Q2 2025 earnings miss, posting an EPS of -0.66 USD against a forecasted -0.2 USD and revenue of 22.3 million USD, substantially below the 27.38 million USD expectation and down sharply year-over-year. This severe underperformance, largely attributed to the ongoing TRICARE payment suspension and sales force restructuring, triggered a 49.2% stock decline in after-hours trading, nearing its 52-week low. The company has suspended quarterly guidance pending a review by its new CEO, Steven Dyson, and aims to achieve positive cash flow by year-end through aggressive cost reductions, while also anticipating FDA approval for its Neko laser pulse oximeter.

Analysis

Zynex Inc. is facing a severe operational and financial crisis, underscored by its Q2 2025 results. The company reported a substantial earnings miss with an EPS of -0.66 USD, far exceeding the -0.2 USD forecast, and a significant revenue shortfall at 22.3 million USD, a steep 55% decline from 49.9 million USD in the prior year. This underperformance triggered a 49.2% collapse in the stock price during after-hours trading, pushing it near its 52-week low. The primary drivers for this downturn are the ongoing temporary payment suspension from TRICARE, a key payer, and the disruptive effects of an aggressive internal restructuring, which includes sales force reductions and adjustments to supply shipment policies. The company's financial position is precarious, with only 17.5 million USD in cash, a high cash burn rate, a current ratio of 0.62 indicating liquidity pressure, and a 60 million USD convertible debt now classified as a current liability due in May 2026. Compounding the uncertainty is a management transition, with a new CEO starting and the current CFO departing, leading to the suspension of all forward-looking guidance. The bull case hinges on two key factors: the successful execution of a 40 million USD annualized cost-reduction plan to achieve positive cash flow by year-end, and the potential FDA clearance of its Neko laser pulse oximeter, a product management believes could be a market disrupter, with a potential approval timeline near the end of the year.

Key Decisions for Investors

• Given the extreme stock volatility and operational distress, investors should treat ZYXI as a high-risk, speculative investment, with its viability heavily dependent on successful debt refinancing and a resolution to the TRICARE payment suspension.
• The primary forward-looking catalyst is the FDA's decision on the Neko pulse oximeter; investors should closely monitor for updates on the expected additional information request in August and any news regarding a potential clearance by year-end.
• Scrutinize upcoming quarterly reports for evidence that the company's aggressive cost-cutting measures are translating into a reduced cash burn and progress toward its goal of positive cash flow, which is critical for near-term survival.
• The combination of a new CEO, a departing CFO, and suspended guidance creates a period of significant uncertainty, making it prudent to wait for the new leadership to provide a clear strategic plan before initiating or adding to a position.